JESSICA CHAO: Open Payments
NPI 1699969659 · BELLEVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 18 payments from 11 companies in 2025. Trend: 2023 $45 · 2024 $148 · 2025 $347
Food & beverage: $347
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
| GENZYME CORPORATION | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Optinose US, Inc. | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| CSL Behring | 1 | $19 |
| ABBVIE INC. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: DUPIXENT, CUVITRU, XOLAIR, Xhance, DAWNZERA, Hizentra, Rhapsido, TRELEGY ELLIPTA.
Industry payments across NJ — which companies pay providers there.
